News: Cadence Pharmaceuticals Inc (CADX.O)
CADX.O on Nasdaq
6.70USD
22 May 2013
6.70USD
22 May 2013
Price Change (% chg)
$-0.29 (-4.15%)
$-0.29 (-4.15%)
Prev Close
$6.99
$6.99
Open
$6.99
$6.99
Day's High
$7.15
$7.15
Day's Low
$6.58
$6.58
Volume
429,196
429,196
Avg. Vol
309,204
309,204
52-wk High
$7.53
$7.53
52-wk Low
$2.56
$2.56
Select another date:
Wed, Dec 12 2012
UPDATE 1-Medicines Co to spend $300 mln to boost hospital products line
* To pay $105 mln to license Bristol-Myers' blood-loss control device
Select another date:
- Cadence's Management Presents at UBS Global Healthcare Conference (Transcript)
- Cadence Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
- 8 Stocks Under $10 Trending Sharply Higher
- SmithOnStocks Opines On Recent Biotech News
- Cadence Pharmaceuticals: Ofirmev Launch Is Strong; Resolution Of Patent Issues Could Be Soon
- Cadence Pharmaceuticals Beats on Both Top and Bottom Lines
Press Releases
- Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
- Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
- Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
- Cadence Pharmaceuticals Announces the Availability of OFIRMEV (acetaminophen) Injection through the VA National Formulary
- Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
- Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV (acetaminophen) Injection
- Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
- Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
- Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
